Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
July 15 2022 - 8:00AM
Business Wire
Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage
biopharmaceutical company focused on the treatment of serious
diseases in which protein growth factors play a fundamental role,
today announced the company will present new data that highlight
the development of its highly selective, context-dependent TGFβ1
antibody that inhibits proTGFβ1 activation selectively in the
context of its extracellular matrix presenting partner, latent TGFβ
binding protein (“LTBP”; the target is collectively identified as
“LTBP-TGFβ1”). The data show reduction of TGFβ1 signaling and
reduction of fibrosis in relevant preclinical models in vivo. These
findings will be presented in an oral and poster presentation at
the 2022 FASEB Science Research Conference (SRC), taking place
between July 17–21, 2022 in Malahide, Ireland.
“TGFβ1 plays a complex role in human disease, including fibrosis
progression and immune regulation. Our earlier work established the
isoform-selective approach to TGFb1 inhibition,” said Gregory
Carven, Ph.D., Chief Scientific Officer of Scholar Rock. “This new
research extends this idea further, showing that highly selective
antibodies that inhibit TGFβ1 associated with specific
extracellular matrix proteins can distinguish between the
profibrotic and immunomodulatory activities of TGFβ1, and could
potentially provide a safe and effective way to treat a wide range
of fibrotic diseases—such as Alport syndrome, scleroderma or
idiopathic pulmonary fibrosis—with a lower potential for
immune-mediated side-effects.”
Data being featured at FASEB SRC will be made available in the
Publications & Posters section of Scholar Rock’s website after
the presentation:
Oral Presentation: Selective Targeting of
Matrix-Associated TGFBeta1 as an Attractive Approach for
Anti-Fibrotic Therapy Presenter: Rohan Manohar, Ph.D.,
Associate Director of Discovery Biology at Scholar Rock
Session: TGF-β Superfamily: Signaling in Development and
Disease Time: July 21, 9:45 a.m. CET
For conference information visit
https://www.faseb.org/meetings-and-events/src-events/the-tgf-%CE%B2-superfamily-conference-signaling-in-development-and-disease.
About Scholar Rock Scholar Rock is a clinical-stage
biopharmaceutical company focused on the discovery and development
of innovative medicines for the treatment of serious diseases in
which signaling by protein growth factors plays a fundamental role.
Scholar Rock is creating a pipeline of novel product candidates
with the potential to transform the lives of patients suffering
from a wide range of serious diseases, including neuromuscular
disorders, cancer, and fibrosis. Scholar Rock’s approach to
targeting the molecular mechanisms of growth factor activation
enabled it to develop a proprietary platform for the discovery and
development of monoclonal antibodies that locally and selectively
target these signaling proteins at the cellular level. By
developing product candidates that act in the disease
microenvironment, the Company intends to avoid the historical
challenges associated with inhibiting growth factors for
therapeutic effect. Scholar Rock believes its focus on biologically
validated growth factors may facilitate a more efficient
development path. For more information, please visit
www.ScholarRock.com or follow Scholar Rock on Twitter
(@ScholarRock) and LinkedIn
(https://www.linkedin.com/company/scholar-rock/). Investors and
others should note that we communicate with our investors and the
public using our company website www.scholarrock.com, including,
but not limited to, company disclosures, investor presentations and
FAQs, Securities and Exchange Commission filings, press releases,
public conference call transcripts and webcast transcripts, as well
as on Twitter and LinkedIn. The information that we post on our
website or on Twitter or LinkedIn could be deemed to be material
information. As a result, we encourage investors, the media and
others interested to review the information that we post there on a
regular basis. The contents of our website or social media shall
not be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended.
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
Forward-Looking Statements This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements regarding Scholar Rock’s future
expectations, plans and prospects, including without limitation,
Scholar Rock’s expectations regarding its growth, strategy, and
progress and indication selection and development timing, the
ability of any product candidate to perform in humans in a manner
consistent with earlier nonclinical, preclinical or clinical trial
data, and the potential of its product candidates and proprietary
platform. The use of words such as “may,” “might,” “could,” “will,”
“should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,”
“project,” “intend,” “future,” “potential,” or “continue,” and
other similar expressions are intended to identify such
forward-looking statements. All such forward-looking statements are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, without limitation, Scholar Rock’s
ability to provide the financial support, resources and expertise
necessary to identify and develop product candidates on the
expected timeline, the data generated from Scholar Rock’s
nonclinical and preclinical studies and clinical trials, and
Scholar Rock’s ability to manage expenses and to obtain additional
funding when needed to support its business activities, as well as
those risks more fully discussed in the section entitled "Risk
Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for the
quarter ended March 31, 2022, as well as discussions of potential
risks, uncertainties, and other important factors in Scholar Rock’s
subsequent filings with the Securities and Exchange Commission. Any
forward-looking statements represent Scholar Rock’s views only as
of today and should not be relied upon as representing its views as
of any subsequent date. All information in this press release is as
of the date of the release, and Scholar Rock undertakes no duty to
update this information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220715005082/en/
Scholar Rock: Investors Rushmie Nofsinger Scholar Rock
rnofsinger@scholarrock.com ir@scholarrock.com 857-259-5573
Media Ariane Lovell Finn Partners
ariane.lovell@finnpartners.com media@scholarrock.com
917-565-2204
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Sep 2023 to Sep 2024